Cite
HARVARD Citation
Cortes, J. et al. (n.d.). Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results. American journal of hematology. 93 (11), pp. 1301-1310. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Cortes, J. et al. (n.d.). Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results. American journal of hematology. 93 (11), pp. 1301-1310. [Online].